These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 39090542)

  • 1. Effect of dapagliflozin on readmission and loop diuretics use in patients with acute heart failure: a retrospective propensity score-matched cohort study.
    Wu D; Ma Z; Wang X; Wang X; Wang X
    BMC Cardiovasc Disord; 2024 Aug; 24(1):402. PubMed ID: 39090542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis.
    Mao L; Cai D; Chi B; Xiao T; Zou A; Wang Y; Chen Q; Gu Q; Wang Q; Ji Y; Sun L
    Eur J Clin Pharmacol; 2023 Jul; 79(7):915-926. PubMed ID: 37099214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
    Cox ZL; Collins SP; Aaron M; Hernandez GA; Iii ATM; Davidson BT; Fowler M; Lindsell CJ; Jr FEH; Jenkins CA; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J
    Am Heart J; 2021 Feb; 232():116-124. PubMed ID: 33144086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.
    Wilcox CS; Shen W; Boulton DW; Leslie BR; Griffen SC
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29440005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
    Jackson AM; Dewan P; Anand IS; Bělohlávek J; Bengtsson O; de Boer RA; Böhm M; Boulton DW; Chopra VK; DeMets DL; Docherty KF; Dukát A; Greasley PJ; Howlett JG; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Ljungman CEA; Martinez FA; O'Meara E; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; Jhund PS; McMurray JJV
    Circulation; 2020 Sep; 142(11):1040-1054. PubMed ID: 32673497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discharge Diuretic Dose and 30-Day Readmission Rate in Acute Decompensated Heart Failure.
    Woodruff AE; Kelley AM; Hempel CA; Loeffler WJ; Echtenkamp CA; Hassan AK
    Ann Pharmacother; 2016 Jun; 50(6):437-45. PubMed ID: 26956954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
    N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of patients eligible for dapagliflozin in acute heart failure.
    Carballo S; Stirnemann J; Garin N; Darbellay Farhoumand P; Serratrice J; Carballo D
    Eur J Clin Invest; 2020 Jun; 50(6):e13245. PubMed ID: 32306388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.
    Carbone S; Canada JM; Billingsley HE; Kadariya D; Dixon DL; Trankle CR; Buckley LF; Markley R; Vo C; Medina de Chazal H; Christopher S; Buzzetti R; Van Tassell BW; Abbate A
    Diabetes Obes Metab; 2018 Aug; 20(8):2014-2018. PubMed ID: 29603546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
    Brisco-Bacik MA; Ter Maaten JM; Houser SR; Vedage NA; Rao V; Ahmad T; Wilson FP; Testani JM
    J Am Heart Assoc; 2018 Sep; 7(18):e009149. PubMed ID: 30371181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous infusion versus bolus injection of loop diuretics for acute heart failure.
    Rasoul D; Zhang J; Farnell E; Tsangarides AA; Chong SC; Fernando R; Zhou C; Ihsan M; Ahmed S; Lwin TS; Bateman J; Hill RA; Lip GY; Sankaranarayanan R
    Cochrane Database Syst Rev; 2024 May; 5(5):CD014811. PubMed ID: 38775253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure.
    Cox ZL; Collins SP; Hernandez GA; McRae AT; Davidson BT; Adams K; Aaron M; Cunningham L; Jenkins CA; Lindsell CJ; Harrell FE; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J
    J Am Coll Cardiol; 2024 Apr; 83(14):1295-1306. PubMed ID: 38569758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Discharged Loop Diuretic Dose to Home Dose on Hospital Readmissions in Patients with Acute Decompensated Heart Failure: A Retrospective Cohort Study.
    Alshibani M; Alshehri S; Alyazidi W; Alnomani A; Almatruk Z; Almeleebia T
    Heart Surg Forum; 2020 Jul; 23(4):E470-E474. PubMed ID: 32726210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.
    Packer M
    Cardiovasc Diabetol; 2019 Oct; 18(1):129. PubMed ID: 31585532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.
    Charaya K; Shchekochikhin D; Andreev D; Dyachuk I; Tarasenko S; Poltavskaya M; Mesitskaya D; Bogdanova A; Ananicheva N; Kuzub A
    Open Heart; 2022 May; 9(1):. PubMed ID: 35609943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
    Shao SC; Chang KC; Lin SJ; Chang SH; Hung MJ; Chan YY; Lai EC
    Cardiovasc Diabetol; 2021 Oct; 20(1):213. PubMed ID: 34688282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.